220 related articles for article (PubMed ID: 20154280)
1. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance.
Idirisinghe PK; Thike AA; Cheok PY; Tse GM; Lui PC; Fook-Chong S; Wong NS; Tan PH
Am J Clin Pathol; 2010 Mar; 133(3):416-29. PubMed ID: 20154280
[TBL] [Abstract][Full Text] [Related]
2. [Differences and clinical significance of receptor expression between primary and locally recurrent breast tumor tissues].
Ma XM; Han YW; Zhang J; Cui WJ; Wang X
Zhonghua Zhong Liu Za Zhi; 2013 May; 35(5):372-6. PubMed ID: 24054015
[TBL] [Abstract][Full Text] [Related]
3. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
[TBL] [Abstract][Full Text] [Related]
4. [Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer].
Wang B; Guan ZZ; Liu DG; Lin TY; Zhang L; Xia ZJ; Teng XY
Ai Zheng; 2004 Dec; 23(12):1710-3. PubMed ID: 15601567
[TBL] [Abstract][Full Text] [Related]
5. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.
Broom RJ; Tang PA; Simmons C; Bordeleau L; Mulligan AM; O'Malley FP; Miller N; Andrulis IL; Brenner DM; Clemons MJ
Anticancer Res; 2009 May; 29(5):1557-62. PubMed ID: 19443366
[TBL] [Abstract][Full Text] [Related]
6. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies.
Amir E; Clemons M; Purdie CA; Miller N; Quinlan P; Geddie W; Coleman RE; Freedman OC; Jordan LB; Thompson AM
Cancer Treat Rev; 2012 Oct; 38(6):708-14. PubMed ID: 22178456
[TBL] [Abstract][Full Text] [Related]
7. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
[TBL] [Abstract][Full Text] [Related]
8. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
9. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
10. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
Monaco SE; Wu Y; Teot LA; Cai G
Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
[TBL] [Abstract][Full Text] [Related]
11. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.
Lindström LS; Karlsson E; Wilking UM; Johansson U; Hartman J; Lidbrink EK; Hatschek T; Skoog L; Bergh J
J Clin Oncol; 2012 Jul; 30(21):2601-8. PubMed ID: 22711854
[TBL] [Abstract][Full Text] [Related]
12. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.
Rossi S; Basso M; Strippoli A; Dadduzio V; Cerchiaro E; Barile R; D'Argento E; Cassano A; Schinzari G; Barone C
Clin Breast Cancer; 2015 Oct; 15(5):307-12. PubMed ID: 25922284
[TBL] [Abstract][Full Text] [Related]
13. [Relationship of oncogene C-erbB2 expression to ER, PR and PS2 in breast cancer and its prognostic significance].
Yang JQ; Chen L; Xing TY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):334-6, 357. PubMed ID: 15181828
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors.
Arnason T; Sapp HL; Barnes PJ; Drewniak M; Abdolell M; Rayson D
Neuroendocrinology; 2011; 93(4):249-58. PubMed ID: 21487213
[TBL] [Abstract][Full Text] [Related]
16. Implications of different CA 15-3 levels according to breast cancer subtype at initial diagnosis of recurrent or metastatic breast cancer.
Park S; Ahn HK; Park LC; Hwang DW; Ji JH; Maeng CH; Cho SH; Lee JY; Park KT; Ahn JS; Park YH; Im YH
Oncology; 2012; 82(3):180-7. PubMed ID: 22433564
[TBL] [Abstract][Full Text] [Related]
17. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
Brown M; Bauer K; Pare M
Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
[TBL] [Abstract][Full Text] [Related]
18. Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors.
Brouckaert O; Pintens S; Van Belle V; Van Huffel S; Camerlynck E; Amant F; Leunen K; Smeets A; Berteloot P; Van Limbergen E; Decock J; Hendrickx W; Weltens C; Van den Bogaert W; Vanden Bempt I; Drijkoningen M; Paridaens R; Wildiers H; Vergote I; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 May; 115(2):349-58. PubMed ID: 18629635
[TBL] [Abstract][Full Text] [Related]
19. Receptor expression discrepancy between primary and metastatic breast cancer lesions.
Karagöz Özen DS; Ozturk MA; Aydin Ö; Turna ZH; Ilvan S; Özgüroglu M
Oncol Res Treat; 2014; 37(11):622-6. PubMed ID: 25427579
[TBL] [Abstract][Full Text] [Related]
20. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
Sharif MA; Mamoon N; Mushtaq S; Khadim MT
J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]